HYUNHO KIM¹, UIJU CHO², SOOK HEE HONG³, HYUNG SOON PARK¹, IN-HO KIM³, HO JUNG AN¹, BYOUNG YONG SHIM¹, JIN HYOUNG KANG^3,*

Oncology Research, Vol.32, No.6, pp. 1021-1030, 2024, DOI:10.32604/or.2024.048919 - 23 May 2024

Abstract Background: Apolipoprotein B mRNA editing catalytic polypeptide (APOBEC), an endogenous mutator, induces DNA damage and activates the ataxia telangiectasia and Rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway. Although cisplatin-based therapy is the mainstay for muscle-invasive bladder cancer (MIBC), it has a poor survival rate. Therefore, this study aimed to evaluate the efficacy of an ATR inhibitor combined with cisplatin in the treatment of APOBEC catalytic subunit 3B (APOBEC3B) expressing MIBC. Methods: Immunohistochemical staining was performed to analyze an association between APOBEC3B and ATR in patients with MIBC. The APOBEC3B expression in MIBC cell lines was assessed… More >

SEUNG-HEE GWAK¹, JUHYUN LEE¹, EUNJI OH¹, DOHYUN LEE^1,2, WONSHIK HAN³, JONGMIN KIM^1,*, KYONG-TAI KIM^4,*

Oncology Research, Vol.32, No.2, pp. 421-432, 2024, DOI:10.32604/or.2023.031031 - 28 December 2023

Abstract Genetic information is transcribed from genomic DNA to mRNA, which is then translated into three-dimensional proteins. mRNAs can undergo various post-transcriptional modifications, including RNA editing that alters mRNA sequences, ultimately affecting protein function. In this study, RNA editing was identified at the 499th base (c.499) of human vaccinia-related kinase 2 (VRK2). This RNA editing changes the amino acid in the catalytic domain of VRK2 from isoleucine (with adenine base) to valine (with guanine base). Isoleucine-containing VRK2 has higher kinase activity than the valine-containing VRK2, which leads to an increase in tumor cell proliferation. Earlier we… More > Graphic Abstract